Bronchial arterial chemoembolization combined with microwave ablation and immunotherapy for the treatment of advanced lung squamous cell carcinoma:a clinical study
10.3969/j.issn.1008-794X.2025.01.010
- VernacularTitle:支气管动脉灌注化疗栓塞术联合微波消融和免疫疗法治疗中晚期肺鳞癌的临床研究
- Author:
Bo YAN
1
;
Penghua LV
;
Fuan WANG
;
Shuxiang WANG
;
Ling SUN
Author Information
1. 225001 江苏扬州 苏北人民医院介入科
- Keywords:
microwave ablation;
bronchial arterial chemoembolization;
immunotherapy;
lung squamous cell carcinoma
- From:
Journal of Interventional Radiology
2025;34(1):64-69
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect and safety of bronchial arterial chemoembolization(BACE)combined with micro wave ablation(MW A)and immunotherapy in treating patients with advanced lung squamous cell carcinoma.Methods The clinical data of 68 patients with advanced lung squamous cell carcinoma,who were admitted to the North Jiangsu People's Hospital of China from June 2020 to June 2022 to receive treatment,were retrospectively analyzed.According to the therapeutic method,the patients were divided into control group(n=30,receiving BACE combined with immunotherapy)and observation group(n=38,receiving BACE followed by MW A,which was performed with CT-guided localization of the lung lesion,and immunotherapy in 3-5 days after BACE).Results The surgical success rate in both the 30 patients of the observation group and the 38 patients of the control group was 100％.After treatment,no surgery-related or chemoembolization-related serious complications occurred in both groups.In the control group and the observation group,the mean progression-free survival(PFS)was(5.70±1.61)months and(12.10±0.72)months respectively,the mean overall survival(OS)was(11.80±1.10)months and(13.00±1.13)months respectively.The PFS of the observation group was obviously longer than that of the control group(P＜0.05),and no statistically significant difference in OS existed between the two groups(P=0.255).Conclusion BACE combined with MW A and immunotherapy can effectively control the advanced lung squamous cell carcinoma,it has reliable short-term efficacy when compared with BACE plus immunotherapy,and it can inhibit tumor growth and prolong the PFS of patients,with a trend of extending OS and a satisfactory clinical safety.
